- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.01. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.25 | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | 4 | GlobeNewswire (USA) | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.12.25 | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | 11 | Investing.com Deutsch | ||
| 17.12.25 | Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential | 1 | Investing.com | ||
| 15.12.25 | Vor Bio raises $150 million in private placement to fund clinical trials | 1 | Investing.com | ||
| 15.12.25 | Vor Bio announces $150M private placement | 5 | Seeking Alpha | ||
| 15.12.25 | Vor Biopharma: Vor Bio Announces $150 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 09.12.25 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | 17 | Investing.com | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target | 6 | Investing.com | ||
| 13.11.25 | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 409 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11.25 | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Vor Biopharma Stock Sinks 48% | 9 | RTTNews | ||
| 11.11.25 | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11.25 | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11.25 | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11.25 | Vor Bio prices $100 million public offering of common stock | 6 | Investing.com | ||
| 11.11.25 | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 305 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,200 | -1,34 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As... ► Artikel lesen | |
| EDITAS MEDICINE | 1,478 | -0,57 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GERON | 1,450 | +3,94 % | Geron Corporation: Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | ||
| SOL GLOBAL INVESTMENTS | 0,064 | +5,63 % | SOL Global Investments Corp.: SOL Global Announces Settlement of Outstanding Debentures | Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCD) (FSE: 9SB0) ("SOL" or the "Company") is pleased to announce that it has satisfied its... ► Artikel lesen | |
| TRINITY BIOTECH | 0,770 | -1,91 % | Trinity Biotech plc: Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement | DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,057 | -0,05 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates | Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,210 | +0,56 % | Arcturus auf Biotech-Gipfel: Strategische Fortschritte bei mRNA-Therapien | ||
| OVID THERAPEUTICS | 1,310 | +9,17 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CERVOMED | 3,820 | -4,98 % | CervoMed Inc.: CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies | Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low... ► Artikel lesen | |
| EQUILLIUM | 1,216 | -8,30 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,350 | -0,11 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| CABALETTA BIO | 2,790 | -2,11 % | Cabaletta Bio-Aktie: Wird sie 2026 erneut zum Biotech-Highflyer? | Die Aktie des ehemaligen sharedeals.de-Tenbaggers Cabaletta Bio wird seit geraumer Zeit wieder mit vorsichtigem Optimismus begleitet, während das Biotech-Unternehmen versucht, eine gentechnisch veränderte... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 31,150 | +7,45 % | Regencell announces one-year extension to insider lock-up commitments | ||
| THX PHARMA | 3,800 | -1,55 % | THERANEXUS: THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex | THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex
Lyon, France - February 12, 2026 - 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company... ► Artikel lesen | |
| LONGEVERON | 0,543 | +1,63 % | Longeveron Appoints Stephen H. Willard as Chief Executive Officer | Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 12,790 Euro und damit -2,37 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.